# Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma

> **NCT01259375** · PHASE2 · COMPLETED · sponsor: **University of Utah** · enrollment: 24 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Amrubicin

## Key facts

- **NCT ID:** NCT01259375
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259375, "Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01259375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*